CR20230310A - Inhibidores de prmt5 - Google Patents

Inhibidores de prmt5

Info

Publication number
CR20230310A
CR20230310A CR20230310A CR20230310A CR20230310A CR 20230310 A CR20230310 A CR 20230310A CR 20230310 A CR20230310 A CR 20230310A CR 20230310 A CR20230310 A CR 20230310A CR 20230310 A CR20230310 A CR 20230310A
Authority
CR
Costa Rica
Prior art keywords
compounds
formula
prmt5 inhibitors
prmt5
inhibitors
Prior art date
Application number
CR20230310A
Other languages
English (en)
Inventor
Matthew Paul Bourbeau
Shon Booker
Nicholas Anthony Weires
Sanne Omholt Schroder Glad
Patricia Lopez
Francesco Manoni
John R Butler
Brian Alan Lanman
Ian Sarvary
Nuria A Tamayo
Liping H Pettus
Mikkel Vestergaard
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CR20230310A publication Critical patent/CR20230310A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/16—Peri-condensed systems

Abstract

Se describen en el presente documento inhibidores novedosos de PRMT5 de Fórmula I y sales farmacéuticamente aceptables de los mismos, así como composiciones farmacéuticas de los mismos. Los compuestos de la presente invención son útiles para inhibir la actividad de PRMT5 y pueden tener uso en el tratamiento de trastornos proliferativos, metabólicos y sanguíneos. Los compuestos de Fórmula I tienen la siguiente estructura:
CR20230310A 2020-12-16 2021-12-15 Inhibidores de prmt5 CR20230310A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063126416P 2020-12-16 2020-12-16
PCT/US2021/063540 WO2022132914A1 (en) 2020-12-16 2021-12-15 Prmts inhibitors

Publications (1)

Publication Number Publication Date
CR20230310A true CR20230310A (es) 2023-09-01

Family

ID=79927288

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230310A CR20230310A (es) 2020-12-16 2021-12-15 Inhibidores de prmt5

Country Status (17)

Country Link
US (2) US11845760B2 (es)
EP (1) EP4263545A1 (es)
JP (1) JP2023550530A (es)
KR (1) KR20230121820A (es)
CN (1) CN116888120A (es)
AR (1) AR124369A1 (es)
AU (1) AU2021400942A1 (es)
CA (1) CA3204823A1 (es)
CL (1) CL2023001738A1 (es)
CO (1) CO2023008167A2 (es)
CR (1) CR20230310A (es)
IL (1) IL303451A (es)
MX (1) MX2023007192A (es)
PE (1) PE20231295A1 (es)
TW (1) TW202233183A (es)
UY (1) UY39565A (es)
WO (1) WO2022132914A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022337201A1 (en) * 2021-08-30 2024-03-07 Amgen Inc. Process for synthesizing naphthyridine derivatives and intermediates thereof
WO2023196545A1 (en) * 2022-04-08 2023-10-12 Amgen Inc. Cancer treatments using mta-cooperative prmt5 inhibitors
WO2024002263A1 (zh) * 2022-06-30 2024-01-04 南京明德新药研发有限公司 氨基取代的杂芳基衍生物及其应用
WO2024002376A1 (zh) * 2022-07-01 2024-01-04 上海赛岚生物科技有限公司 一类prmt5抑制剂及其用途
WO2024021957A1 (zh) * 2022-07-26 2024-02-01 上海和誉生物医药科技有限公司 一种prmt5抑制剂及其制备方法和药学上的应用
WO2024027370A1 (zh) * 2022-08-03 2024-02-08 上海和誉生物医药科技有限公司 一种含氮三稠环prmt5抑制剂，其制备方法和药学上的用途
WO2024038004A1 (en) 2022-08-15 2024-02-22 Astrazeneca Ab Mta-cooperative prmt5 inhibitors for use in the treatment of cancer
WO2024037459A1 (zh) * 2022-08-18 2024-02-22 南京明德新药研发有限公司 含酰胺的杂环衍生物及其应用
CN117658980A (zh) * 2022-09-08 2024-03-08 郑州同源康医药有限公司 双环类prmt5抑制剂
WO2024067445A1 (zh) * 2022-09-26 2024-04-04 上海湃隆生物科技有限公司 新型prmt5抑制剂及其应用
CN115677708A (zh) * 2022-10-19 2023-02-03 五邑大学 一种吡咯并喹喔啉的制备方法
US11845749B1 (en) 2023-07-13 2023-12-19 King Faisal University Substituted pyrido[4′,3′:5,6]pyrazino[1,2-a]indoles as anticancer agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106573932B (zh) 2014-08-22 2019-07-30 默克专利股份公司 吲唑类
JP2020530496A (ja) * 2017-08-09 2020-10-22 プレリュード セラピューティクス，インコーポレイティド タンパク質アルギニンメチルトランスフェラーゼ５（ｐｒｍｔ５）の選択的阻害剤
US20210277009A1 (en) * 2018-08-07 2021-09-09 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US20210309687A1 (en) * 2018-08-07 2021-10-07 Merck Sharp & Dohme Corp. Prmt5 inhibitors
JP2023513580A (ja) * 2020-02-12 2023-03-31 アムジェン インコーポレイテッド 新規ｐｒｍｔ５阻害剤

Also Published As

Publication number Publication date
CL2023001738A1 (es) 2023-11-17
US20240092794A1 (en) 2024-03-21
IL303451A (en) 2023-08-01
CA3204823A1 (en) 2022-06-23
JP2023550530A (ja) 2023-12-01
AR124369A1 (es) 2023-03-22
PE20231295A1 (es) 2023-08-22
CN116888120A (zh) 2023-10-13
CO2023008167A2 (es) 2023-07-21
UY39565A (es) 2022-06-30
AU2021400942A1 (en) 2023-07-06
US11845760B2 (en) 2023-12-19
EP4263545A1 (en) 2023-10-25
KR20230121820A (ko) 2023-08-21
WO2022132914A1 (en) 2022-06-23
MX2023007192A (es) 2023-07-03
TW202233183A (zh) 2022-09-01
US20220194955A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
MX2023007192A (es) Inhibidores de prmt5.
MX2022010011A (es) Inhibidores de prmt5 novedosos.
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
GEP20237561B (en) Protein tyrosine phosphatase inhibitors
MX2023006145A (es) Inhibidores de prmt5 novedosos.
MX2022005053A (es) Inhibidores de peque?as moleculas de mutante g12c de kras.
PH12018500212A1 (en) 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
EA201000341A1 (ru) 2-анилинопурин-8-оны в качестве ингибиторов ttk/mps1 для лечения пролиферативных нарушений
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
MX2023005636A (es) Inhibidores de bcl6 derivados de bencimidazolona.
EA201991916A1 (ru) 1,4,6-ТРИЗАМЕЩЕННЫЕ-2-АЛКИЛ-1H-БЕНЗО[d]ИМИДАЗОЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ДИГИДРООРОТАТНЫХ ОКСИГЕНАЗНЫХ ИНГИБИТОРОВ
MX2021010106A (es) Inhibidores de la via de respuesta al estres integrada.
WO2014106800A8 (en) Substituted 2-amino pyrimidine derivatives as kinase inhibitors
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
MX2023006504A (es) Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo.
MX2022012056A (es) Pirrolopirimidinaminas como inhibidores del sistema del complemento.
CR20220538A (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso
MX2021014372A (es) Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos.
MX2021013942A (es) Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton.
MX2022007171A (es) Compuestos cíclicos y métodos de uso de estos.
MX2021009206A (es) Terapias contra el cancer.
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy